Table 3.

Growth factor–associated adverse events on cycles 1 to 4 by treatment arm

PegfilgrastimFilgrastim
Patients/cycles17/6317/68
Toxicity (patients/episodes)
    Mucositis (grade ≥2)4/47/9
    Bone pain (grade ≤2)3/43/3
    Increased hepatic transaminases (grade ≤2)6/75/8
    Increased hepatic transaminases (grade 3)1/11/1
Median (range) number of transfusions
    Packed RBC transfusions1 (0-4)3 (0-6)
    Platelet transfusions0 (0-4)0 (0-3)